Grade 2 grow at a moderate speed. You have tests to find out the size of the NET and whether it has spread. This is your stage. Doctors use your stage to plan your treatment. There are different ways ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

The approval for use in advanced neuroendocrine tumors is supported by data from ... delays in disease progression in the CABINET trial—regardless of primary tumor site and grade,” said Jennifer Chan, ...

SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs ... Standard treatment for grade 1/2, non-functional, unresectable GEP-NETs is ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment ... a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical efficacy ...

in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors in the phase III COMPETE trial, ITM Isotope ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.